| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
12,610 |
11,151 |
$3.64M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,003 |
6,275 |
$1.29M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,042 |
3,517 |
$1.23M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,898 |
3,404 |
$555K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
974 |
896 |
$438K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,789 |
11,213 |
$308K |
| 80053 |
Comprehensive metabolic panel |
11,225 |
9,220 |
$296K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,258 |
4,533 |
$248K |
| 36415 |
Collection of venous blood by venipuncture |
14,233 |
11,497 |
$242K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,947 |
1,462 |
$236K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,822 |
2,209 |
$229K |
| 71045 |
Radiologic examination, chest; single view |
4,583 |
3,866 |
$220K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,245 |
2,054 |
$203K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,441 |
1,318 |
$194K |
| 81000 |
|
10,806 |
9,033 |
$187K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,114 |
1,846 |
$172K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
582 |
544 |
$163K |
| 59025 |
Fetal non-stress test |
1,281 |
622 |
$144K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,701 |
2,227 |
$140K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
933 |
637 |
$127K |
| 71046 |
Radiologic examination, chest; 2 views |
2,224 |
1,971 |
$119K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,706 |
4,838 |
$115K |
| 80306 |
|
3,509 |
2,840 |
$114K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
993 |
931 |
$108K |
| G0378 |
Hospital observation service, per hour |
602 |
497 |
$102K |
| 93041 |
|
2,252 |
1,993 |
$99K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,015 |
787 |
$94K |
| 84484 |
|
3,207 |
2,656 |
$85K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,168 |
3,789 |
$81K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,498 |
400 |
$77K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
589 |
524 |
$69K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
624 |
558 |
$68K |
| 87631 |
|
364 |
332 |
$60K |
| 81025 |
|
1,658 |
1,462 |
$56K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,386 |
2,757 |
$51K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,989 |
1,688 |
$48K |
| 83690 |
|
1,787 |
1,552 |
$48K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,143 |
1,857 |
$47K |
| 86900 |
|
1,012 |
825 |
$46K |
| 86850 |
|
1,766 |
1,550 |
$45K |
| 85007 |
|
2,345 |
1,947 |
$44K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
424 |
376 |
$42K |
| 80061 |
Lipid panel |
1,745 |
1,650 |
$39K |
| 85730 |
|
1,508 |
1,337 |
$35K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
774 |
680 |
$35K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
774 |
684 |
$35K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,237 |
1,017 |
$34K |
| 85610 |
|
1,845 |
1,593 |
$34K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
661 |
608 |
$32K |
| 84439 |
|
1,222 |
1,099 |
$32K |
| 73564 |
|
387 |
309 |
$30K |
| 86901 |
|
940 |
825 |
$30K |
| 82550 |
|
926 |
781 |
$28K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
920 |
764 |
$27K |
| 83880 |
|
1,479 |
1,195 |
$27K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,183 |
1,138 |
$26K |
| J3490 |
Unclassified drugs |
623 |
323 |
$25K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,327 |
1,256 |
$24K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
533 |
410 |
$24K |
| 82947 |
|
1,541 |
1,334 |
$23K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
85 |
77 |
$22K |
| 87186 |
|
980 |
859 |
$21K |
| 87077 |
|
867 |
769 |
$20K |
| 87205 |
|
1,333 |
1,157 |
$20K |
| 86803 |
|
560 |
495 |
$20K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
337 |
302 |
$20K |
| 88142 |
|
348 |
306 |
$19K |
| 87040 |
|
954 |
842 |
$19K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
250 |
159 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
367 |
327 |
$18K |
| J2704 |
Injection, propofol, 10 mg |
297 |
242 |
$17K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
238 |
140 |
$16K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
179 |
176 |
$16K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
333 |
228 |
$16K |
| 73030 |
|
269 |
237 |
$15K |
| 87653 |
|
382 |
348 |
$15K |
| 74018 |
|
286 |
252 |
$15K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
16 |
12 |
$15K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
345 |
285 |
$14K |
| 82150 |
|
488 |
430 |
$14K |
| 73610 |
|
219 |
192 |
$13K |
| 87340 |
|
314 |
283 |
$13K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
313 |
284 |
$13K |
| 83605 |
|
710 |
620 |
$13K |
| 36600 |
|
185 |
151 |
$13K |
| 86592 |
|
413 |
367 |
$12K |
| 85027 |
|
1,585 |
1,295 |
$12K |
| 86762 |
|
255 |
233 |
$12K |
| 82805 |
|
186 |
156 |
$11K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
239 |
221 |
$11K |
| 87081 |
|
415 |
381 |
$10K |
| 94760 |
|
193 |
98 |
$9K |
| 73630 |
|
160 |
142 |
$9K |
| 80081 |
|
99 |
81 |
$9K |
| 82951 |
|
585 |
492 |
$9K |
| 84702 |
|
175 |
135 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
272 |
262 |
$7K |
| 73110 |
|
88 |
78 |
$6K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
41 |
39 |
$6K |
| 73502 |
|
88 |
81 |
$6K |
| 85379 |
|
277 |
264 |
$6K |
| 83735 |
|
509 |
424 |
$6K |
| 82607 |
|
160 |
151 |
$5K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
82 |
58 |
$4K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
32 |
26 |
$4K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
96 |
93 |
$3K |
| 85651 |
|
136 |
128 |
$3K |
| 80076 |
|
242 |
224 |
$3K |
| 73130 |
|
54 |
41 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
14 |
12 |
$3K |
| 84703 |
|
150 |
138 |
$3K |
| 96376 |
|
119 |
91 |
$3K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
320 |
255 |
$3K |
| 93971 |
|
15 |
12 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
51 |
36 |
$2K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
14 |
13 |
$2K |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
110 |
102 |
$2K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
156 |
138 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
17 |
16 |
$2K |
| 87420 |
|
32 |
26 |
$2K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
13 |
13 |
$2K |
| 76536 |
|
14 |
14 |
$2K |
| 51702 |
|
31 |
26 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
381 |
258 |
$2K |
| 86140 |
|
43 |
38 |
$1K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
83 |
68 |
$1K |
| 72110 |
|
15 |
15 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
26 |
21 |
$734.98 |
| 85018 |
|
33 |
25 |
$707.59 |
| 85014 |
|
33 |
25 |
$707.58 |
| 97162 |
|
12 |
12 |
$688.53 |
| 87076 |
|
22 |
16 |
$603.08 |
| 87280 |
|
21 |
19 |
$532.98 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
15 |
12 |
$531.47 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
13 |
13 |
$508.32 |
| 82247 |
|
18 |
12 |
$466.80 |
| 82746 |
|
41 |
39 |
$430.66 |
| 84132 |
|
17 |
12 |
$404.53 |
| 82435 |
|
17 |
12 |
$404.53 |
| 84295 |
|
17 |
12 |
$404.53 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
15 |
14 |
$341.25 |
| 73140 |
|
14 |
13 |
$328.87 |
| 82728 |
|
12 |
12 |
$209.99 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
15 |
14 |
$173.86 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
13 |
12 |
$110.94 |
| 83540 |
|
13 |
12 |
$80.93 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
37 |
31 |
$54.18 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
17 |
13 |
$28.92 |